Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?

Jun 16 2017

• By Derrick Gingery

Launch Plans words stamped in red ink on yellow envelope offering advice, information

Related Content

Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK

May 24 2017

Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same

May 25 2017

CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

Aug 03 2016

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

Sep 22 2016

Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism

Jul 21 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

Biosimilar Prescribing Decisions May Depend Upon Disease State

Oct 25 2016

FDA Biosimilar Education Campaign Will Need To Be Targeted

Sep 17 2015

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

Related Companies

Hospira, Inc.

Pfizer Inc.

Amgen, Inc.

Johnson & Johnson

CVS Health Corp.

Novartis AG

Sanofi

Eli Lilly and Company

Additional Topics

United States Biosimilars Advisory Committees Market Access Market Intelligence Regulation BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window